Teprotumumab for the Treatment of Active Thyroid Eye Disease

Douglas RS; Kahaly GJ; Patel A; Sile S; Thompson EHZ; Perdok R; Fleming JC; Fowler BT; Marcocci C; Marinò M; Antonelli A; Dailey R; Harris GJ; Eckstein A; Schiffman J; Tang R; Nelson C; Salvi M; Wester S; Sherman JW; Vescio T; Holt RJ; Smith TJ

doi:10.1056/nejmoa1910434

← Today's brief

Study

Teprotumumab for the Treatment of Active Thyroid Eye Disease

Douglas RS et al. · The New England journal of medicine · Thursday, January 23, 2020

Funding Not reported

Source

Douglas RS et al.. Teprotumumab for the Treatment of Active Thyroid Eye Disease. The New England journal of medicine. Thursday, January 23, 2020.
doi:10.1056/nejmoa1910434Read original ↗

Generated, then checked claim-by-claim against the source · how this brief was built →

Physician-designed methodology · Amr Saad, MD MBA

Automated evidence summary, checked against the source. Not medical advice. Verify with the original publication.